The Cambridgeshire, England-based biopharmaceutical company reported a pretax loss of GBP10.6 million in 2024, widened from GBP8.9 million in 2023. Revenue was GBP5.1 million, up 10% from GBP4.6 ...

VK2735 is a dual agonist of the glucagon like peptide one or GLP-1 ... Viking believes it will have access to a commercial supply of API, auto injectors, vial and syringe kits and oral tablets ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1 ... loss medication fully covered by insurance. About 20% of injection users pay the entire cost out of pocket.

and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss. The 2.5 mg dose is priced at Rs 3,500 per injection, with a monthly cost of Rs ...

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

And when do you plan on introducing the auto-injector into the Phase 3? A: The top line data from the Oral study will likely be reported before the four-week follow-up data are available. The ...

Disabling Fast Startup prevents Windows from entering a hybrid shutdown state, which can sometimes lead to unexpected issues like auto shutdowns after inactivity. By turning it off, the system ...

Atishay Ltd has been successfully qualified and empaneled as a Business Partner with ITI Limited, a Government of India ...

Viking Therapeutics reported a net loss of $0.41 per share for Q1 2025, missing analysts’ expectations of $0.33 loss per share. Following the earnings announcement, Viking Therapeutics’ stock ...

For moderate to severe hypoglycemia due to diabetes, a prescription medication containing the hormone glucagon can be delivered by injection or nasal inhalation. Hypoglycemic emergencies ...